Orchid Pharma Reports 15% Revenue Growth in Q1 FY27 Post-Merger

Orchid Pharma's revenue from operations climbed 15% to INR 304 crore in the first quarter of FY27, compared to INR 263 crore in the same period last year. The company presented restated combined results following its merger with Dhanuka Laboratories, which became effective July 10, 2026.

EBITDA saw a substantial jump to INR 25 crore from INR 10 crore in Q1 FY26, with gross margins expanding by approximately 3 percentage points to 33%.

Reader Takeaway: Merger integration yields revenue growth and margin improvement, but cyclical headwinds persist.

What just happened

Orchid Pharma announced its Q1 FY27 financial results, reflecting the combined entity after its merger with Dhanuka Laboratories. Revenue from operations reached INR 304 crore, a 15% increase from the previous year. EBITDA improved to INR 25 crore, and gross margins expanded to 33%.

Why this matters

The results indicate successful integration post-merger, showing top-line growth and enhanced profitability. Improved margins and EBITDA suggest better operational efficiency and product mix.

The backstory

On a combined basis, FY26 revenue was INR 1,233 crore, a decrease from FY25's INR 1,398 crore, which the company attributed to challenging conditions in the cephalosporin business. The merger with Dhanuka Laboratories was finalized with an appointed date of April 1, 2024.

What changes now

Shareholders will see a consolidated financial performance reflecting the merged entity. Key projects like the 7-ACA project in Jammu and the Cefiderocol facility are progressing, aiming to bolster future revenue streams and vertical integration.

Risks to watch

Management acknowledges ongoing pricing pressures and overcapacity in the cephalosporin API market, particularly in non-regulated markets. Execution risks for large fermentation projects and regulatory dependencies for new product launches, like Cefiderocol, remain critical watch points.

Peer comparison

While specific peer results aren't in the filing, the company's commentary highlights a competitive landscape for cephalosporin API manufacturers, indicating similar pressures may affect competitors.

Context metrics (time-bound)

• Q1 FY27 Revenue: INR 304 crore (vs INR 263 crore in Q1 FY26)
• Q1 FY27 EBITDA: INR 25 crore (vs INR 10 crore in Q1 FY26)
• Q1 FY27 Gross Margin: 33% (vs 30% in Q1 FY26)
• 7-ACA Project Capex: INR 750 crore
• Cefiderocol Facility Capex: USD 20-25 million
• Exblifep Russia Licensing: USD 178 million (estimated 10-year value)

What to track next

Investors should monitor the commissioning of the 7-ACA project by March 2027 and the readiness of the Cefiderocol facility by December 2026. Regulatory approvals for Cefiderocol and volume growth in global markets for Exblifep will be key indicators.